Application of donor dendritic cells-mediated recipient lymphocyte reaction after living related kidney transplantation in individualized immunosuppressive therapy
10.3760/cma.j.issn.0254-1785.2011.09.003
- VernacularTitle:供者DC介导的淋巴细胞反应在肾移植后个体化免疫抑制治疗中的作用
- Author:
Chibing HUANG
;
Xiaoting XU
;
Mingqi FAN
;
Jiayu FENG
;
Genfu ZHANG
;
Pingxian WANG
;
Ya XIAO
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Donors;
Dendritic cells;
Immune reaction
- From:
Chinese Journal of Organ Transplantation
2011;32(9):519-522
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the feasibility of mediating recipient lymphocyte reaction with donor dendritic cells (DCs) in renal allograft recipients to guide individualized inmunosuppressive therapy. Methods From Jan. 2008 to Jan. 2010, 30 recipients received living related kidney transplantation were successively and divided into 2 groups according to the strategies of the correction of the dosage of immunosuppressant, 15 in each group. The strategy of immunosuppressive therapy in both groups was Tac + MMF + Pred. The correction of the dosage of immunosuppressant in experimental group was conducted by recipient lymphocyte reaction with donor DC (LR) combined with Tac and MPA blood concentration monitoring. Only blood concentration monitoring of drugs was applied in control group. Examinations of liver and renal function, blood and urine routine as well as blood sugar were done monthly for 1 year. ResultsDuring the follow-up period, the rate of acute rejection in experimental group and control group was 13. 3 ％ and 46. 7 ％ respectively (P＜0. 05) ;the rate of infection in experimental group and control group was 6. 7％ and 40. 0％ (P＜0. 05)respectively; the adverse reaction rate in experimental group and control group was 13. 3％ and 46. 7％(P＜0. 05). There was no significant difference in the serum creatinine level between the two groups at each observation point. ConclusionThe application of combined recipient LR with donor DC and blood concentration monitoring of drugs in individualized irnmunosuppressive therapy is more comprehensive and accurate.
